Questions in consideration

1. What key assets are required to deliver the value proposition?

Developing a medicine, particularly for cancer therapy, as a company requires a complete approach that includes a variety of critical assets in order to effectively offer the value proposition. These assets include scientific, regulatory, economic, and strategic realms, guaranteeing that the treatment not only satisfies therapeutic requirements but also achieves a profitable outcome. The study on the effect of brown seaweed fucoidan on breast cancer advancement establishes a solid basis, emphasising the value of creative research and development, also known as R&D, as a crucial asset. The following are the major assets required:

a) Innovative R&D.
The capacity to conduct research and development is the foundation of any drug development company. This comprises a highly experienced research staff, cutting-edge facilities, as well as access to cutting-edge technology. The study on fucoidan highlights the need of having a robust R&D foundation to identify and evaluate new pharmaceutical targets and mechanisms(Djurian et al., 2020).

b) IP Protection
Protecting the intellectual property rights of discoveries, such as the medicinal use of fucoidan in cancer treatment, is critical. Patents and trademarks protect the company's ideas, giving it a competitive advantage and guaranteeing an earnings on investment(Wu et al., 2016).

c) Regulatory expertise
Navigating the complicated regulatory landscape is critical to medication approval. Expertise in regulatory issues is required to guarantee compliance with the rules of regulatory authorities such as the FDA or EMA. Understanding the regulatory pathways can expedite the drug approval process(Djurian et al., 2020).

d) Clinical research and trials.
Efficient clinical trial plans and execution are critical. This includes the capacity to undertake Phase I-IV clinical studies, which ensure the drug's efficacy and safety. Collaborations with clinical research organisations (CROs) along with access for patient populations are valuable advantages.

e) Manufacturing and Supply Chain.
The capacity to produce the medicine at scale while maintaining quality control is critical. This comprises facilities for manufacturing, packaging, and distribution. A strong supply chain enables effective medicine delivery to the market.

f) Marketing and Sales Strategy
A smart sales and marketing plan is critical to the drug's successful commercialization. This comprises market analysis, branding, price strategies, and a sales team that can promote the medicine to healthcare providers.

g) Financial Resources.
The development of drugs is a highly capital-intensive process. Financial resources, including venture capital, partnerships, and public funding, are essential for supporting R&D, clinical trials, and market entry.

h) Strategic Partnerships
Collaborations with research organisations, industrial partners, and healthcare organisations can give valuable knowledge, resources, and technology access. Partnerships can speed up drug development and improve market access.

i) Patient Action and Engagement
Participating in patient communities and organisations that advocate can give valuable insights into patient preferences and requirements. This participation is critical for clinical trial recruitment and understanding the market landscape.

j) Compliance and ethics
It is critical to uphold ethical practices and comply with legal and regulatory norms. This encompasses ethical behaviour in clinical studies, confidentiality of information, and patient safety1.In conclusion, establishing a medicine as a company involves a comprehensive approach that combines scientific innovation, such as fucoidan's therapeutic promise in cancer therapy, with strategic, legal, and financial planning. These assets

all contribute to achieving the value proposition, ensuring that the medicine satisfies clinical requirements and achieves economic success.

2. Are these resources available at a reduced cost?

Innovative development and research (R&D) is expensive because it requires qualified researchers, modern lab facilities, and access to the latest technologies. Educational institutions or funded by the government research centres may provide more cost-effective solutions for early-stage R&D than commercial pharmaceutical corporations. Protection of intellectual property through trademarks and patents may be expensive, particularly for small enterprises and startups. Regulatory knowledge and negotiating complicated approval processes may be time-consuming, therefore working with contract research organisations or regulatory consultancy may give more cost-effective alternatives. Clinical trial expenses can be high, however options exist through academic or government-funded networks, patient advocacy groups, or doing studies in lower-cost countries. Manufacturing along with supply chain skills need considerable capital investment, while contract manufacturing companies can provide more cost-effective solutions for smaller production quantities. Both sales and marketing strategies can use digital platforms and focused efforts to cut expenses. Financial resources are essential, and small enterprises or new businesses may have access to venture funding, government subsidies, or public-private partnerships. Strategic collaborations with universities, industry leaders, or non-profit organisations can give access to resources, skills, and technology at potentially cheaper prices.

3. What can be rented, leased or borrowed rather than purchased?

The study article recommends various possible resources for entrepreneurs researching fucoidan-based drugs. These include leasing or renting lab space from colleges and universities, research parks, or incubators, which may give access to advanced equipment and instruments at a lesser cost than acquiring them outright. Collaboration with contract manufacturing organisations (CMOs) may enable companies to access existing production facilities and knowledge without requiring major financial commitment. Clinical trial infrastructure might be sourced from existing networks, patient advocacy organisations, or university medical centres, allowing access to patient populations and trial structure without direct ownership. Regulatory knowledge is critical for medication clearance, and startups might consider hiring or leasing the services of regulatory consultants or specialised businesses.
Intellectual Property (IP) protection might be investigated by leasing or licencing patented technology or intellectual property from academic institutions or research organisations. Equipment and apparatus may be rented or leased from specialised suppliers, or shared equipment facilities at academic or research institutes. For data analysis, modelling, and simulations, computational resources can be rented via cloud computing services or high-performance computer resources from service providers. Co-working spaces, incubators, and shared office providers all provide office space and facilities for hire or lease. The study article implicitly emphasises the usefulness of diverse resources for startups in lowering capital and operational expenses during the drug development process.

4. Are there any intangible resources such as Brand, data, information, Knowledge that you need to re-inforce?

The paper discusses the importance of scientific knowledge, regulatory expertise, clinical trial data, bioinformatics capabilities, intellectual property (IP) portfolio, industry knowledge, and collaborations with academic institutions. It emphasizes the need for a startup to have a deep understanding of the therapeutic effects of fucoidan on breast cancer cells, as well as a robust IP portfolio of patents, trademarks, and trade secrets related to fucoidan's therapeutic use.

Regulatory knowledge is also crucial for navigating the complex regulatory landscape for drug approval. The paper describes various experimental methods and assays used to study fucoidan's effects, such as cell viability, invasion, and gene expression assays. Bioinformatics capabilities and expertise in data analysis are also essential for interpreting and leveraging this data.

Industry knowledge and market intelligence are also crucial for a startup to develop effective business strategies and commercialization plans. Collaborations with academic institutions, industry players, or patient advocacy groups can serve as intangible resources, providing access to knowledge, expertise, and resources.
In summary, the paper underscores the importance of various intangible resources for a startup to develop a drug based on fucoidan's therapeutic potential.

sources

DJURIAN, A., MAKINO, T., LIM, Y., SENGOKU, S. & KODAMA, K. 2020. Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs. *Sustainability,* 12**,** 5535.

WU, S. Y., WU, A. T., YUAN, K. S. & LIU, S. H. 2016. Brown Seaweed Fucoidan Inhibits Cancer Progression by Dual Regulation of mir-29c/ADAM12 and miR-17-5p/PTEN Axes in Human Breast Cancer Cells. *J Cancer,* 7**,** 2408-2419.